financetom
Business
financetom
/
Business
/
ASGN Q2 Adjusted Earnings, Revenue Fall; Q3 Outlook Issued -- Shares Fall After-Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ASGN Q2 Adjusted Earnings, Revenue Fall; Q3 Outlook Issued -- Shares Fall After-Hours
Jul 24, 2024 3:09 PM

05:43 PM EDT, 07/24/2024 (MT Newswires) -- ASGN ( ASGN ) reported Q2 adjusted net income late Wednesday of $1.36 per diluted share, down from $1.59 per share a year ago.

Analysts polled by Capital IQ expected $1.33.

Revenue for the quarter ended June 30 fell to $1.04 billion from $1.13 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.05 billion.

For Q3, the company expects adjusted EPS of $1.31 to $1.39 on revenue of $1.02 billion to $1.04 billion.

The consensus is for $1.46 and $1.07 billion, respectively.

The company's shares were down about 3.8% in after-hours activity.

Price: 98.00, Change: -3.83, Percent Change: -3.76

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Premier American Uranium Completes Acquisition of Nuclear Fuels
Premier American Uranium Completes Acquisition of Nuclear Fuels
Sep 16, 2025
TORONTO, Sept. 16, 2025 /PRNewswire/ - Premier American Uranium Inc. ( PAUIF ) (PUR or Premier American Uranium) (TSXV: PUR)  and Nuclear Fuels Inc. ( NFUNF ) (NF or Nuclear Fuels) (CSE: NF) are pleased to announce the completion of the previously announced arrangement (the Arrangement) whereby Premier American Uranium ( PAUIF ) has acquired all of the issued and...
Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™
Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™
Sep 16, 2025
SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Medicines360, a women’s health innovation organization with a mission to be a catalyst for change, today announced that it has acquired global licensing rights to PeriPeach, an investigational medical device designed to prevent severe perineal tears during birth, from Fruits of Labor, Inc. PeriPeach will now advance through the 360 Innovation Hub,...
Market Chatter: Eli Lilly's Weight-Loss Pill May Get FDA Approval by Year-End
Market Chatter: Eli Lilly's Weight-Loss Pill May Get FDA Approval by Year-End
Sep 16, 2025
07:43 AM EDT, 09/16/2025 (MT Newswires) -- Eli Lilly's ( LLY ) investigational oral weight-loss drug orforglipron could be approved by the US Food and Drug Administration before the end of the year under a new one-to-two-month priority review process, Reuters reported Tuesday, citing Wall Street analysts. Analysts see the drug as a strong candidate for the fast-track program, which...
The Ether Machine Announces Confidential Submission of a Draft Registration Statement on Form S-4 with the SEC
The Ether Machine Announces Confidential Submission of a Draft Registration Statement on Form S-4 with the SEC
Sep 16, 2025
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Ether Machine, a planned public company following a pending business combination with Dynamix Corporation ( ETHM ) (“Dynamix”) and The Ether Reserve LLC, announced today the confidential submission by The Ether Machine of a draft registration statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”).  Andrew Keys,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved